Established in 2017, Elpis is a pre-clinical stage biopharmaceutical company.
Our vision is to become a leading biotech company by developing innovative biological and cellular therapeutics for difficult-to-treat cancers.
Through our proprietary antibody discovery and protein engineering platforms, we are advancing a rich pipeline to treat solid tumors and hematological malignancies with the goal of improving outcomes for patients with difficult-to-treat and resistant cancers.
Our strategy includes:
- Develop and commercialize wholly owned programs
- Collaboration or out-licensing of pipeline program
- Research collaborations to discover lead candidates for partner’s preferred targets
Locations in USA and China